In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate ...

Namenda XR) are both used to treat dementia symptoms in people with Alzheimer’s disease, but they work in different ways. One drug may be better at helping certain symptoms than the other drug.

New York-based Forest Laboratories is testing Namenda (memantine), an Alzheimer's drug and N-methyl D-aspartate receptor (NMDA) receptor modulator, in a phase 2 trial in autism patients.

Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs. By Gina Kolata and Rebecca Robbins A daily pill may be as ...

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several ...

Illustration: Elizabeth Smelov The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP-1 drugs Mounjaro and Ozempic ...